LFG
LXEO icon

Larson Financial Group’s Lexeo Therapeutics LXEO Stock Holding History

Larson Financial Group’s Portfolio LXEO Stock Details LXEO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-1,456
Closed -$8.36K – 3874
2026
Q1 		$8.36K Buy
1,456
+1,216
+507% +$8.62K ﹤0.01% 2348
2025
Q4 		$2.38K Buy
240
+235
+4,700% +$2.14K ﹤0.01% 2726
2025
Q3 		$33 Buy
+5
New +$24 ﹤0.01% 3373

Other funds holding LXEO

SCM
Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return
AAA
Affinity Asset Advisors New York $2.21B AUM 431.26% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return

Larson Financial Group's LXEO Position: Q2 2026 in Review

Larson Financial Group sold out of Lexeo Therapeutics (LXEO) in Q2 2026, closing a stake of 1,456 shares — an estimated $8.36K sold.

Larson Financial Group first reported a position in LXEO in Q3 2025 and held it in 3 quarters. The position peaked at $8.36K in Q1 2026. 141 funds tracked by Wall St. Rank hold LXEO as of Q2 2026.

  • Larson Financial Group reported no remaining Lexeo Therapeutics position as of Q2 2026 after selling out during the quarter.
  • Larson Financial Group sold 1,456 Lexeo Therapeutics shares in Q2 2026, an estimated $8.36K.
  • Larson Financial Group first reported a position in Lexeo Therapeutics in Q3 2025 and held it in 3 quarters.
  • Larson Financial Group's Lexeo Therapeutics position peaked at $8.36K in Q1 2026.
  • 141 funds tracked by Wall St. Rank held Lexeo Therapeutics as of Q2 2026.

Based on Larson Financial Group's 13F filing for Q2 2026, filed 14 Aug 2026.